HNF4α Re-expression Reverses Cirrhosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cirrhosis, a condition characterized by liver dysfunction, are limited, with no effective methods to reverse hepatocyte dysfunction and improve liver function, leading to the need for new therapeutic approaches.
Innovation Solution
The use of hepatocyte nuclear factor 4 alpha (HNF4α) as a transcription factor, either through agonists, nucleic acid molecules, proteins, or functional fragments, to restore hepatocyte function by re-expressing HNF4α in cirrhotic animals, thereby improving liver function and survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cirrhosis are used, then patient survival is extended, but liver function cannot be reversed and definitive therapy requires transplantation
Solution Approach 1:
The patent uses HNF4α agonists as intermediary substances to mediate between the cirrhotic liver tissue and the desired therapeutic outcome. These agonists act as molecular mediators that bind to HNF4α receptors on hepatocytes, triggering intracellular signaling cascades that reverse dysfunction without requiring complex surgical intervention or organ transplantation.
Solution Approach 2:
The patent changes the biochemical parameters of hepatocytes by introducing HNF4α agonists that modify gene expression profiles, protein synthesis patterns, and cellular metabolic states. This transforms the physiological state of liver cells from dysfunctional to functional, reversing cirrhosis without physical structural changes or transplantation.
2Reliability
If hepatocytes are replaced through transplantation, then liver function is restored, but the procedure is complex and not definitively curative
Solution Approach 1:
The patent enables the liver to self-repair by activating endogenous HNF4α pathways through agonist administration. The hepatocytes themselves perform the repair function by upregulating protective genes and restoring metabolic functions, eliminating the need for external transplantation procedures and making treatment accessible without complex surgical infrastructure.
Solution Approach 2:
Instead of replacing damaged hepatocytes with transplanted cells, the patent uses HNF4α agonists to create functional copies of healthy hepatocyte behavior within the existing damaged cells. The agonists induce expression of genes and proteins that replicate the functional characteristics of normal hepatocytes, achieving restoration without physical replacement.
3Reliability
If HNF4α is re-expressed to correct hepatocyte phenotype, then liver function improves, but the mechanism requires understanding complex transcriptional regulation
Solution Approach 1:
The patent extracts and isolates the critical therapeutic element (HNF4α agonist activity) from the complex web of transcriptional regulation. By focusing on this single key pathway and using small molecule agonists that specifically target HNF4α, the patent simplifies the therapeutic approach while maintaining effectiveness, making the mechanism more detectable and measurable through specific biomarker assays.
Data Source
AI summary
The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4α; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.